These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2964031)

  • 1. [Efficacy of pipobroman in the treatment of essential thrombocythemia].
    Bauters F; Jouet JP; Simon M; Pollet JP; Fenaux P; Walter MP
    Presse Med; 1988 Jan; 17(2):81. PubMed ID: 2964031
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
    Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C
    Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pipobroman therapy of essential thrombocythemia.
    Mazzucconi MG; Francesconi M; Chistolini A; Falcione E; Ferrari A; Tirindelli MC; Mandelli F
    Scand J Haematol; 1986 Oct; 37(4):306-9. PubMed ID: 3787181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
    Passamonti F; Cazzola M
    Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
    [No Abstract]   [Full Text] [Related]  

  • 5. Pregnancy in a young woman affected by essential thrombocythemia: a case report.
    Ferrari A; Mazzucconi MG; Martinelli E; Giona F; Paesano R; Pachi A
    Haematologica; 1989; 74(1):115-6. PubMed ID: 2498176
    [No Abstract]   [Full Text] [Related]  

  • 6. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman.
    Messora C; Bensi L; Vanzanelli P; Temperani P; Carotenuto M; Sacchi S
    Haematologica; 1996; 81(1):51-3. PubMed ID: 8900853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow aplasia after pipobroman: an immune-mediated mechanism?
    Triffet A; Straetmans N; Ferrant A
    Br J Haematol; 2001 Dec; 115(3):713-4. PubMed ID: 11736962
    [No Abstract]   [Full Text] [Related]  

  • 8. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.
    Passamonti F; Malabarba L; Orlandi E; Pascutto C; Brusamolino E; Astori C; Baratè C; Canevari A; Corso A; Bernasconi P; Cazzola M; Lazzarino M
    Br J Haematol; 2002 Mar; 116(4):855-61. PubMed ID: 11886392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
    Passamonti F; Rumi E; Malabarba L; Arcaini L; Orlandi E; Brusamolino E; Pascutto C; Cazzola M; Lazzarino M
    Ann Hematol; 2004 Aug; 83(8):495-7. PubMed ID: 15175894
    [No Abstract]   [Full Text] [Related]  

  • 11. Practical approach to treating essential thrombocythaemia: case studies.
    Reilly JT
    Eur J Haematol Suppl; 2007 Oct; (68):40-2. PubMed ID: 17727566
    [No Abstract]   [Full Text] [Related]  

  • 12. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
    Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F
    Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
    Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary thrombocythemia.
    Jamshidi K; Ansari A; Windschitl HE; Swaim WR
    Geriatrics; 1973 Jan; 28(1):121-33. PubMed ID: 4539498
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset.
    Orlandi E; Bernasconi P; Boni M; Calatroni S; Lazzarino M
    Ann Hematol; 2005 Feb; 84(2):127-8. PubMed ID: 15378276
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution.
    De Sanctis V; Mazzucconi MG; Spadea A; Alfò M; Mancini M; Bizzoni L; Peraino M; Mandelli F
    Br J Haematol; 2003 Nov; 123(3):517-21. PubMed ID: 14617017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent trends in therapy of chronic myeloproliferative disorders].
    Fuse I
    Nihon Naika Gakkai Zasshi; 1993 Jul; 82(7):1058-62. PubMed ID: 7693834
    [No Abstract]   [Full Text] [Related]  

  • 18. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
    Randi ML; Fabris F; Girolami A
    Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
    [No Abstract]   [Full Text] [Related]  

  • 19. [Little known treatment of primary polycythemia: pipobroman (apropos of 19 cases)].
    Bauters F; Jouet JP; Goudemand M
    Lille Med; 1976 Mar; 21(3):202-8. PubMed ID: 950881
    [No Abstract]   [Full Text] [Related]  

  • 20. [Management of polycythaemia with pipobroman].
    Perreau-Boutet MC; Najman A; Stachowiak J; Parlier Y; Gorin NC; Duhamel G
    Nouv Presse Med; 1982 Sep; 11(34):2549-53. PubMed ID: 7133977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.